Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817-26
D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-24
Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-20
Sipponen T, Björkesten CG, Färkkilä M, Nuutinen H, Savilahti E, Kolho KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010;45:325-31
De Vos M, Dewit O, D'Haens G, et al.; behalf of BIRD. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis 2012;6:557-62
van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic metaanalysis. BMJ. 2010;341:c3369. doi: 10.1136/bmj.c3369
Kennedy NA, Clark A, Walkden A, et al. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50years. J Crohns Colitis. 2014 Aug 15. pii: S1873-9946(14)00218-9. doi: 10.1016/j.crohns.2014.07.005
Mooiweer E, Severs M, Schipper M, et al. Low fecal calprotectin predicts sustained clinical remission in 1 inflammatory bowel disease patients: a plea for deep remission. J Crohn Colitis 2014;9:50-5
Molander P, Färkkilä M, Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFa-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis. 2014 Jul 19. pii: S1873-9946(14)00209-8. doi: 10.1016/j.crohns.2014.06.012
Lasson A, Stotzer PO, Ohman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2014 Jul 5. pii: S1873-9946(14)00185-8. doi: 10.1016/j.crohns.2014.06.002
Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60
Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13
D'Incà R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429-37
Mindemark M, Larsson A. Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem 2012;45:552-5
Baert F, Moortgat L, Van Assche G, et al.; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8
Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301
Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian populationbased cohort. Gastroenterology 2007;133:412-22
Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:483-489
Louis E, Mary JY, Vernier-Massouille G, et al.; Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70
D'Incà R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-14
Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8
García-Sánchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 2010;4:144-52
Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;28:1221-9
Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174-8
Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20
Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012;107:1684-92
De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013;19:2111-7
Elkjaer M, Burisch J, Voxen Hansen V, Deibjerg Kristensen B, Slott Jensen JK, Munkholm P. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther 2010;31:323-30
Naismith GD, Smith LA, Barry SJ, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther 2013;37:613-21
Osterman MT, Aberra FN, Cross R, et al.; on behalf of the DEAR Investigators. Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis. Clin Gastroenterol Hepatol. 2014 Apr 30. pii: S1542-3565(14)00635-1. doi: 10.1016/j.cgh.2014.03.035. [Epub ahead of print]